XSOLLA
8.8.2024 18:01:37 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the opening of its first Canadian office in Montreal in collaboration with GameAddik. This strategic expansion into one of North America's most dynamic tech hubs underscores Xsolla's dedication to innovation and its mission to better serve the burgeoning gaming industry and developers in Quebec and across Canada.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808870268/en/
(Graphic: Xsolla)
Montreal has long been recognized for its dynamic gaming ecosystem and innovative tech community. By establishing a presence in this thriving city, Xsolla aims to expand its operations with incredible local talent and foster closer relationships with regional developers. The new office will serve as a hub for Xsolla's operations in Canada, enhancing its ability to offer tailored and localized solutions to its current partners and thousands of new game developers and publishers in the region.
"Montreal is renowned for its dynamic gaming ecosystem and innovative tech community. Our presence here will enable us to better support our local and global partners and tap into the incredible local talent pool," said Xsolla's president, David Stelzer. “This new office in Montreal will be crucial in strengthening our relationships with local game developers and facilitating our mission to empower our partners to reach their full potential.”
As part of this expansion, Xsolla plans to hire up to 50 regional employees over the next two years, targeting a mix of roles in business development, customer support, and technical services. This investment will strengthen its capacity to deliver cutting-edge solutions and exceptional service.
This strategic partnership with GameAddik originated from the successful cross-service opportunities explored with its dedicated marketing solution, GameRebellion, creating a robust support system for game developers in Canada.
"We are excited about our collaboration with Xsolla, as our GameRebellion project shares a common vision of empowering studios to achieve greater success," said Alain Carpentier, CTO at GameAddik.
"Our partnership with Xsolla is a game-changer for GameAddik," said Eric Jodoin, CEO of GameAddik. "Teaming up with such a prominent company allows us to better support the industry in striving for success."
The new office will be a one-stop shop for companies looking for industry-leading and cutting-edge solutions to fund, launch, market, monetize, and sell their games to local gamers and fans of their games worldwide. Xsolla provides advanced tools and services to help game developers accelerate their business by reaching players who want to pay for their gaming experiences locally using their preferred payment methods. With the ability to enable transactions in over 130 currencies and 20 languages, Xsolla has already facilitated access to new gamers for game developers worldwide.
For more information about the Xsolla Canadian office, please visit xsolla.pro/montreal.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com.
About GameAddik
Founded in 2015, GameAddik is an advertising technology company that provides tech-driven marketing solutions for the gaming industry. Trusted by over 200 global brands, GameAddik is a leader in understanding gaming audiences and delivering measurable performance marketing solutions for its clients across its three business segments: PWN Games (performance marketing), Elusive (performance-driven influencer marketing), and GameRebellion (game audience and industry data and analytics).
For more information, please visit gameaddik.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808870268/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom